PRMT5 and glioblastoma: Genetic suppression10,13–15 and pharmacological inhibition of PRMT5 in mouse, zebrafish, and human GBM models both result in growth suppression, providing a rationale for further investigation of this druggable target on the tumorigenic subpopulation14,16,17.